89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)
A Pilot Study of 89Zr-DFO-REGN3767 Anti LAG-3 Antibody Positron Emission Tomography in Patients With Relapsed/Refractory DLBCL
Sponsor: Memorial Sloan Kettering Cancer Center
This EARLY_PHASE1 trial investigates DLBCL and Large B-cell Lymphoma and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 12 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
May 2025 — Present [monthly]
Completed EARLY_PHASE1
-
Apr 2025 — May 2025 [monthly]
Completed EARLY_PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2024 — Apr 2025 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting EARLY_PHASE1
▶ Show 7 earlier versions
-
Nov 2023 — Jul 2024 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — Nov 2023 [monthly]
Recruiting EARLY_PHASE1
-
Apr 2022 — Nov 2022 [monthly]
Recruiting EARLY_PHASE1
-
May 2021 — Apr 2022 [monthly]
Recruiting EARLY_PHASE1
-
Jan 2021 — May 2021 [monthly]
Recruiting EARLY_PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting EARLY_PHASE1
-
Oct 2020 — Dec 2020 [monthly]
Recruiting EARLY_PHASE1
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .